The European Medicines Agency is not ready to join Project Orbis, the US FDA’s framework for concurrent international review of oncology applications, but will be watching the process more closely as an observer going forward.
The move seems almost anti-climactic given that the EMA and the FDA already work together closely on cancer products. EMA...








